Data published in the peer-reviewed journal shows positive results for SNG001 in hospitalised COVID-19 patients
#SYGGF "announced the publication of data from the Company’s #SG016 trial in The Lancet Respiratory Medicine journal. The SG016 trial randomized 101 hospitalized COVID-19 patients to either SNG001, Synairgen’s inhaled formulation of interferon beta-1a, or placebo. Positive topline results from the trial were originally announced on 20 July 2020, with more detailed results of primary endpoint analyses disclosed in the Company's 2020 Interim Results on 29 September 2020.
The double-blind, randomized, placebo-controlled trial assessed the efficacy and safety of inhaled SNG001 as a therapy for patients hospitalized with COVID-19. Patients were randomized (1:1) to receive SNG001 or placebo by inhalation via a mouthpiece once daily for 14 days. The primary endpoint was the change in clinical condition using the WHO Ordinal Scale for Clinical Improvement (OSCI) during the dosing period in the intention-to-treat population (ITT).
SNG001 was shown to be well tolerated and patients who received the drug had greater odds of improvement and recovered more rapidly. Patients receiving SNG001 had greater odds of improvement across the OSCI scale (OR 2·32; 95% CI: 1·07, 5·04; p=0·033) and were more likely to recover to “no limitation of activity” during treatment (HR 2·19; 95% CI: 1·03, 4·69; p=0·043). There were three deaths in the placebo group and none in the SNG001 group.
The full title of the publication is: "Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo- controlled, phase 2 trial” (see press release HERE).
See our SYGGF COVID AmpCard HERE.